Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment
Table 3
Blindness and visual impairment outcomes in patients with neovascular age-related macular degeneration with and without monthly treatment with ranibizumab.